Mometasone Biogaran (Mometasone Furoate Anhydrous)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nasal passages. This binding alters gene expression, suppressing the release of inflammatory mediators, reducing swelling, and limiting immune cell infiltration, which together diminish nasal inflammation.

The appropriate dose of Mometasone Biogaran is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mometasone furoate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone furoate is a high‑potency corticosteroid with a favorable safety profile when used as directed. Compared with agents such as fluticasone, it offers similar anti‑inflammatory efficacy but may require a lower daily dose, potentially reducing the risk of systemic exposure.

The nasal spray should be stored at temperatures below 25 °C, protected from moisture and direct sunlight. Keep the product in its original packaging until use and avoid exposing it to extreme heat or humidity to maintain potency.

Mometasone Biogaran is administered as a nasal spray. The patient tilts the head slightly forward, inserts the nozzle into one nostril, and sprays the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious but rare risks include nasal septal perforation, elevated intraocular pressure that may lead to glaucoma, and systemic adrenal suppression when used at high doses for prolonged periods. Patients should report any unusual symptoms such as persistent nosebleeds, vision changes, or severe fatigue.

Individuals with known hypersensitivity to mometasone furoate or any component of the formulation should avoid the product. It is also contraindicated in patients with untreated bacterial, fungal, or viral infections of the nasal passages unless specifically directed by a physician.